GlassScriptPhysician profile
Chad J Brock
NPI 1588691794
$15,551.19
in general payments reported to CMS, 2019-2025
41 companies · $2,108 in 2025
The $2,108 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,940 · 2020: $1,800 · 2021: $2,234 · 2022: $1,767 · 2023: $2,814 · 2024: $2,887 · 2025: $2,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,804 · Education: $5.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,804.45 |
| Education | $5.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,893.23 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,351.57 | 2019-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,080.81 | 2019-2024 | Trintellix |
| Axsome Therapeutics, INC. | $913.42 | 2023-2025 | Auvelity, Sunosi |
| Neos Therapeutics, LP | $754.15 | 2019-2025 | Adzenys Xr-Odt, Exxua |
| Corium, LLC | $710.21 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $689.01 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $630.94 | 2019-2023 | Spravato, Invega Sustenna |
| Allergan, INC. | $607.06 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $593.45 | 2019-2025 | Fanapt |
| Alkermes, INC. | $585.64 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $543.00 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $542.33 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $539.48 | 2022-2025 | Caplyta |
| Avanir Pharmaceuticals, INC. | $444.78 | 2019-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $399.98 | 2019-2023 | |
| Ironshore Pharmaceuticals INC. | $375.05 | 2019-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $358.26 | 2019-2024 | Austedo Xr, Austedo |
| Adlon Therapeutics L.P. | $313.43 | 2019-2021 | |
| Lundbeck LLC | $312.33 | 2019-2024 | Rexulti |
| Tris Pharma INC | $266.97 | 2022-2024 | Dyanavel Xr |
| Indivior INC. | $253.34 | 2021-2025 | Sublocade |
| Bausch Health US, LLC | $174.05 | 2019-2025 | Aplenzin, Wellbutrin |
| Eisai INC. | $154.45 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $110.57 | 2025 | Cobenfy |
| Braeburn INC. | $100.28 | 2023-2025 | Brixadi |
| Shire North American Group INC | $100.26 | 2019 | |
| Collegium Pharmaceutical, INC. | $96.18 | 2025 | Jornay Pm |
| Orexo US, INC. | $94.57 | 2019-2021 | |
| Harmony Biosciences LLC | $94.11 | 2020-2023 | Wakix |
| Idorsia Pharmaceuticals US INC | $88.58 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $85.68 | 2024-2025 | Xelstrym |
| Merck Sharp & Dohme LLC | $70.93 | 2019-2020 | |
| Uswm, LLC | $56.74 | 2021 | |
| Vivus LLC | $38.32 | 2021 | |
| Brainsway USA INC | $31.20 | 2019-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $22.00 | 2025 | Lumryz |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.44 | 2025 | |
| Owp Pharmaceuticals, INC. | $20.36 | 2021 | |
| Alfasigma USA, INC. | $17.18 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Brock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.